Skip to content


Journal of Hematology & Oncology

Open Access

New insights on low-grade and T-cell lymphoma

Journal of Hematology & Oncology20092(Suppl 1):A3

Published: 26 June 2009


Public HealthLymphomaCancer ResearchTherapeutic AgentAdvanced Disease

The advances in low-grade lymphoma & T-cell lymphoma from the 2008 ASH meeting were presented. These included therapeutic regimens for low grade lymphoma, frontline bendamustine plus rituximab data, radioimmunotherapy consolidation in advanced disease, idiotype vaccine, and other novel therapeutic agents such as next generation anti-CD20 GA101, syk inhibitor Fostamatinib in treatment of low-grade lymphoma. In T-cell lymphoma, updates were discussed on phase II HOVON 69 trial data of combination of alemtuzumab/CHOP, pralatrexate and romidepsin for relapsed/refractory PTCL, L-asparaginase-containing regimen for extranodal NK/T-cell lymphoma.

Authors’ Affiliations

University of Colorado Cancer Center, Denver, USA


© Tse; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.